HA
Haleos Labs Limited (HALEOSLABS)
₹1,490.00
Mkt cap
₹453 Cr
P/E ratio
28.60
P/B
2.11
Div yield
0.10%
ROE
8.44%
ROCE
9.91%
EPS (TTM)
₹52.10
Book value
₹706
52W range
1,091–1,774
Sector
Healthcare
Price history
Previous close
Incorporated in 2006, SMS Lifesciences Ltd is in the business of manufacturing of Active Pharma Ingredients and their intermediates [1]
NSE HALEOSLABSBSE 540679
Health check
Cautious
ValuationCheap
ProfitabilityWeak
GrowthLow
TechnicalsNeutral
52-week range
−16.01% from high₹1,490
₹1,091+36.56% from low₹1,774
Current
₹1,490.00
Prev close
₹1,501.40
Day
−0.76%
Price performance
1D
−0.76%
1W
−0.89%
1M
+0.68%
3M
−8.64%
6M
+19.86%
1Y
+25.79%
YTD
+10.04%
Financials
Revenue, profit & margin
P/E ratio
28.6×
HALEOSLABS is 17% below the sector median of 34.6×
HALEOSLABS28.6×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 74.65 | 69.26 | 72.05 | 89.99 | 92.55 | 78.46 | 84.60 | 89.11 | 82.50 | 81.37 | 94.78 | 75.14 | 72.94 | |
| Expenses | 72.11 | 61.33 | 62.75 | 78.63 | 76.27 | 69.89 | 71.85 | 81.69 | 70.79 | 67.79 | 80.73 | 70.98 | 63.82 | |
| Operating Profit | 2.54 | 7.93 | 9.30 | 11.36 | 16.28 | 8.57 | 12.75 | 7.42 | 11.71 | 13.58 | 14.05 | 4.16 | 9.12 | |
| OPM % | 3.40% | 11.45% | 12.91% | 12.62% | 17.59% | 10.92% | 15.07% | 8.33% | 14.19% | 16.69% | 14.82% | 5.54% | 12.50% | |
| Other Income | 0.61 | 0.27 | 0.58 | 2.36 | 0.44 | 2.04 | 0.06 | 2.34 | 1.00 | 0.42 | 0.18 | 2.01 | 0.46 | |
| Interest | 2.18 | 2.81 | 2.34 | 2.84 | 2.40 | 2.14 | 2.14 | 2.03 | 1.87 | 1.62 | 1.54 | 1.42 | 1.90 | |
| Depreciation | 3.70 | 3.73 | 3.73 | 3.78 | 3.68 | 3.76 | 3.76 | 3.80 | 3.82 | 3.89 | 3.91 | 3.85 | 4.24 | |
| Profit before tax | -2.73 | 1.66 | 3.81 | 7.10 | 10.64 | 4.71 | 6.91 | 3.93 | 7.02 | 8.49 | 8.78 | 0.90 | 3.44 | |
| Tax % | 40.29% | 126.51% | -8.14% | 8.73% | 33.27% | 29.72% | 29.81% | 11.45% | 37.61% | 24.38% | 24.26% | 62.22% | 46.51% | |
| Net Profit | -3.83 | -0.44 | 4.12 | 6.47 | 7.10 | 3.30 | 4.86 | 3.48 | 4.39 | 6.42 | 6.65 | 0.35 | 1.84 | |
| EPS in Rs | -5.95 | 2.25 | 14.22 | 19.52 | 23.15 | 15.45 | 18.09 | 9.82 | 13.76 | 20.18 | 21.90 | 1.46 | 8.77 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −7.27% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 5 Aug '26 |
| Earnings day | −7.27% |
| +1 day | −6.55% |
| +5 days | −5.73% |
| +15 days | −2.51% |
| +30 days | −3.03% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202672.10%Promoter
Promoters72.10%
FIIs0.00%
DIIs0.31%0.01
Public27.58%0.01
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Haleos Labs Limited | ₹1,497.60 | 28.64 | 453 | 0.10% | 2 | −36.30% | 73 | −11.59% | 9.91% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports10
Concall transcripts1
Credit ratings6
Announcements5
USFDA Update (Material Subsidiary) 18 Sep - USFDA inspection at Mahi Drugs facility concluded with zero Form 483 observations on September 18, 2026.Annual Report (Weblink) 9 Sep - 20th AGM on September 30, 2026; dividend record date September 23, 2026; e-voting September 26-29.Newspaper Advertisement (AGM Notice) 8 Sep - 20th AGM on Sept 30, 2026; dividend Rs 1.50/share recommended; e-voting dates Sept 26-29, 2026.AGM Notice (Sept 30, 2026) 8 SepReg. 34 (1) Annual Report. 8 Sep - Haleos Labs filed FY26 annual report; AGM on 30 Sept 2026; board recommends ₹1.50 dividend.